Canadian Gilead Sciences Inc. has announced being granted a Notice of Compliance (NOC) by Health Canada for its ODEFSEY™ tablets as a complete drug for the treatment of adults infected with HIV-1 infection. ODEFSEY becomes the latest product from Gilead Canada’s tray of tenofovir alafenamide (TAF) to be certified. Others are DESCOVY™ and GENVOYA®.
ODEFSEY is identified in Canada as a complete medical treatment of adults with HIV-1. TAF mainly targets tenofovir that have shown high levels of antiviral efficacy with similarities to or at a lesser dose that one-tenth of the Gilead’s VIREAD®.
TAF has also shown significant improvement in the making of renal and bones compared to TDF used in clinical when combined with other antiretroviral agents. Data indicates that due to the fact that TAF load cells more effectively and efficiently that the TDF it can be administered in smaller dosages. This results in a less than 90% reduced concentration of tenofovir, the blood system.
According to Dr. Stephen Shafran, Professor of Medicine at University of Alberta’s Division of Infectious Diseases says people infected with the HIV virus are likely to be treating other health conditions like liver, kidney and heart-rated diseases. This is due to the fact that they are living longer than previous years which increase the period of exposure of the patients with the virus and the antiviral medications used in its treatment. He adds that there is need to develop new drugs that have minimal effects, easy to adapt to and easy to dose.
Dr. Shafran adds that clinical findings have shown that TAF has been improving in renal laboratory measures as compared to TDF.
Gilead Canada’ General Manager Kennet Brysting says ODEFSEY will offers an alternative to supporting patients who are not used to using antiretroviral drugs as well as patients who may need to replace an older antiretroviral drug to whom the virus has become a mutant. He adds that the main goal these days goes beyond reaching undetectable status because available medication is able to address longer-term effects of the drug to enable patients live quality lifestyles.